Expert Referral Services
Life Science Discovery and Development
Whether you are conducting early-stage research or preparing for clinical trials, we connect you with the right expertise to help accelerate your work. Our consultant referral services cover a wide range of specialized fields, including chemistry and biology.
We are looking for experts in the life science field to help our entrepreneurs. Please contact info@acmebay.net to become a member. The experts are listed alphabetically based on the last name.
Steven J Coats, PhD
Education: PhD - Emory University (1994 Albert Padwa); Postdoc - Yale University (1996 Harry Wasserman)
Areas of Expertise: Accomplished pharmaceutical R&D scientific researcher, vice president, senior director and mentor with almost 30 years’ experience in large, small and start-up pharmaceutical companies. Major career focuses on drug discovery, design, optimization along with pre-clinical R&D, safety assessment and the translation of discovery research small molecules into clinical development across multiple therapeutic areas. Extensive experience in synthetic chemistry management and hands-on organic chemistry spanning a diverse variety of molecule classes. Excellent communication and proven leadership skills.
Experience: 30 years pharmaceutical drug discovery experience. Vice President of Chemistry at OncoSpherix, director of chemistry at Cocrystal Pharma and RFS Pharma. See LinkedIn for more details.
Principle location: Atlanta Metropolitan
Contact: chemcoatsconsulting@gmail.com; Steve Coats | LinkedIn
Titan Gu, PhD
Education: Ph.D. – Columbia University (Biophysical Chemistry, 1996): Postdoc – Memorial Sloan Kettering Cancer Center (1996-1997); U. Penn (1997-1998)
Areas of Expertise: CMC project management, Analytical Development, Quality Control, troubleshooting and problem solving of DS/DP manufacturing, Quality Assurance (GMP), Regulatory Affair, IND/NDA preparation and filing, Domestic and international CDMO partnering/collaboration/GMP auditing, Bioanalytical chemistry, Met ID and structural characterization.
Experience: Nearly 30 years of experience in the pharmaceutical and biotech industries, including senior leadership roles such as SVP at PharmaBlock and VP at Theravance. Held various positions at 3M Pharmaceuticals, GSK, and Procter & Gamble Pharmaceuticals, with expertise spanning CMC project management, Analytical Development, DS/DP manufacturing (PPQ, Site transfer), Quality, Regulatory Affairs, DMPK, and Bioanalytical Chemistry.
Bernd Jandeleit, PhD
Education: PhD, MS (1992-1995, D. Enders, RWTH Aachen, Germany), Postdoc (1995-1997, K.C. Nicolaou, The Scripps Research Institute, La Jolla, CA, USA)
Areas of Expertise: Scientific Leadership, Teambuilding & Mentoring, Corporate & Project Management, Organic & Medicinal Chemistry, Drug Discovery & Development, Small Molecules & Prodrugs, DMPK, ADMET, Metabolite ID, Chemical Process Development, IP protection, Grant Applications (SBIR), Radiochemistry, (Bio)conjugation & Click Chemistry
Experience: Postdoc (’95-’97), Symyx Technologies, Inc. (’98-‘00), XenoPort, Inc. (‘00-‘10), Quadriga BioSciences, Inc. (’10-’20), Kodiak Sciences Inc. (’20-’24), Maxymune Therapeutics, Inc. (’25-present), and Jandeleit Lifesciences Consulting, LLC (’10-present)
Contact: bernd.jandeleit@outlook.com, Bernd Jandeleit | LinkedIn
Daniel E. Levy, PhD
Education: MIT, Ph.D. in Organic Chemistry (1992, S. Masamune)
Areas of Expertise: Synthetic Organic Chemistry, Medicinal Chemistry, Route Scouting, Manufacturing Process Development/Optimization, GMP Manufacturing of Drug Substance and Drug Product, CMC Services, IND Module 3 Drafting, Domestic and international CDMO partnering/collaboration.
Experience: 30+ years industrial experience covering all aspects of pharma research and development from early stage medicinal chemistry to clinical/commercial manufacturing.
Contact: dan@delbiopharmallc.com, www.delbiopharma.com, Daniel Levy | LinkedIn
Stuart G Levy, PhD
Education: PhD, Chemistry (UIC, Robert M Moriarty, 1992); Postdoctoral Fellow in Medicinal Chemistry (UCSD School of Medicine)
Areas of Expertise: Synthetic organic chemistry, chemical process research and development, CMC, GMP manufacturing, preformulation, solid state chemistry, API manufacturing, drug product process development and manufacturing, troubleshooting and resolution of API manufacturing, drug product manufacturing, and analytical problems, synthesis of stable isotope and radiolabeled drugs, stereochemistry, asymmetric syntheses and classical and dynamic kinetic resolutions, enabling technologies for poorly absorbed and poorly soluble lead and development candidate molecules, preparation, review, and editing of regulatory documentation and submissions.
Experience: 30 years of industrial small molecule new chemical entity (NCE) chemical and pharmaceutical development experience. 15 years as a permanent employee in roles of increasing responsibility, primarily at entrepreneurial startup biotechs (SUGEN, EPIX, Elixir, PPD Dermatology) and two CDMOs (SERES Laboratories, Ricerca). 20 years as a CMC leader with accumulated practical experience in drug product R&D and development. 15 years as an independent, sole-proprietor consultant for very small to medium sized biotech companies all over the US. Medivation, Ariad Pharmaceuticals, Nimbus Therapeutics, IGM, Cullinan, US WorldMeds, and Neumora Therapeutics are among the higher-profile clients that I have served as a consultant. More than 26 years of involvement in evaluation, selection, engagement, and oversight/leadership of external third party vendors for chemistry and CMC services on behalf of employers and elients. 10 years as an expert witness in Hatch-Waxman Paragraph IV litigation. Breadth as well as depth.
Contact: sglevy@yahoo.com, stuartlevy@sglchemistryconsultingllc.com, Stuart G Levy | Web, Stuart G Levy | LinkedIn
Fuqiang Liu, PhD
Education: Ph.D. Organic Chemistry, (Emory University 1996, Lanny Liebeskind)
Areas of Expertise: Process chemistry, CMC Regulatory Affairs, project management, CRDMO management, U.S. site operation for Chinese pharmaceutical companies, FDA IND/NDA CMC review.
Experience: Over 28 years of pharmaceutical experience, at JNJ, GSK, FDA and multiple Chinese pharmaceutical/biotech companies. Leading successful IND, ANDA and NDA submission/approval to/by the FDA for different Chinese companies.
Contact: Fqliu2007@yahoo.com, Fuqiang Liu | LinkedIn
Gary C Look, PhD
Education: Ph.D. – UC Irvine (LE Overman); Postdoc – The Scripps Research Institute (CH Wong)
Areas of Expertise: Early Preclinical Services: Preclinical planning from discovery through IND-enabling studies, chemistry, DMPK, toxicology, efficacy models, data analysis, NIH and DoD grant writing, Small molecule medicinal and process chemistry consultation, Intellectual property generation and management. Research and Development Operations: Discovery project management, timelines, budgets, CRO selection, qualification, management, study management, protocol design and review. Specializing in small companies with limited budgets
Experience: 30+ years of experience in the biotech industry: Affymax Research Institute, MetaXen, Protein Design Labs, Rigel Pharmaceuticals, Acumen Pharmaceuticals.
Contact: lookbiopharma@gmail.com, www.lookbiopharma.com
Publications: Please Click Here
Neil Raheja, PhD
Education: Ph.D. Organic Chemistry (Wayne State University, Carl Johnson 1996)
NIH Postdoc (U of Pennsylvania, Amos Smith III and Prof Ralph Hirschmann,1996-1998)
Areas of Expertise: Experience in all aspects of drug discovery from early discovery and target evaluation, through lead discovery and evaluation, to candidate nomination and development.
Experience: Medicinal chemist with > 25yrs drug discovery experience at Pfizer, Celgene, January Therapeutics. 15 NME’s moved into clinical development as project leader or team member. Experience in company formation, asset due diligence, fundraising, and CRO management. Worked in Oncology, I&I, cardiovascular/metabolic disease, dermatology, and CNS therapeutic areas. Expertise in all target classes and therapeutic modalities including targeted protein degradation.
Contact: nraheja@integrated-pharma.com, Neil Raheja | LinkedIn
Hing Sham, PhD
Education: PhD - University of Hawaii, Synthetic Organic Chemistry; post-doc - Indiana University
Areas of Expertise: Drug discovery, from lead discovery to phase 1.
Experience: 36 years pharmaceutical experience. Co-inventor marketed drug – Ritonavir, Lopinavir; clinical candidate ABT-751…
Contact: hinglsham@gmail.com, Hing Sham | LinkedIn
Hing Sham | YouTube
Rick Shin, PhD
Education: Ph.D. – Carleton University (D.C. McIntyre; Canada); Postdoc – National Institute on Drug Abuse (S. Ikemoto; Maryland)
Areas of Expertise: Early preclinical discovery through IND-enabling studies of small molecules in CNS (psychiatry, epilepsy, neurodegeneration) and endocrinology with expertise in areas of pharmacology, DMPK, toxicology, in vivo and in vitro efficacy models. Experience in CRO management of pharmaceuticals, medical devices, leachables and extractables testing using GLP, ISO, USP, ASTM, and ICH standards.
Experience: 15 years experience in biotech, big pharma and CRO industries: Astellas, MD Anderson Cancer Center, Crinetics Pharmaceuticals, Pacific BioLabs, Atai Life Sciences, Cognition Therapeutics.
Contact: rickshin621@gmail.com, Rick Shin | LinkedIn
Jianhong Wang, PhD
Education: Ph.D. Analytical Chemistry (Iowa State University, 1997)
Areas of Expertise: ADME/PK support from early discovery through regulatory filing, including small-molecule lead optimization, human PK/dose projection, DDI risk assessment, gap analysis, non-compartmental & compartmental PK analysis/modeling, IND-enabling ADME/PK study design & oversight, clinical formulation development support, PK/PD support, GLP bioanalysis, human 14C mass balance study design & oversight, and regulatory documents preparation.
Experience: DMPK scientist with ~25 years of experience in drug discovery and development at Array BioPharma, Gilead, Ideaya Biosciences and Cortexyme. Led the nonclinical team that supported the NDA approval of Biktarvy®, a multibillion-dollar HIV treatment.
Contact: jianhong022@gmail.com, Jianhong Wang | Web, Jianhong Wang | LinkedIn
Suresh Yeola, PhD
Education: PhD (Organic Chemistry)
Areas of Expertise: Drug Metabolism and Pharmacokinetics (DMPK). Experience in early discovery through post IND studies of small molecules in Hepatitis C, cystic fibrosis, irritable bowel disease (IBD) and chronic obstructive pulmonary disease (COPD) with expertise in the areas of in vivo and in vitro biotransformation, DMPK, toxicology. Experience in CRO management of pharmaceutical, DMPK studies and radiolabeled ADME studies
Experience: 30 years experience in biotech, small and big pharma: Forest Labs,
Bristol Myers Squibb, Vertex Pharmaceuticals, Theravance Biopharma.
Contact: snyeola@gmail.com; Suresh Yeola | Linkedin
